☆ 4.8 Article

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

CELL REPORTS (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Lauren B. Rodda et al.

Summary: The study found that individuals recovered from mild COVID-19 develop sustained SARS-CoV-2-specific immunological memory for at least 3 months, including immunoglobulin antibodies, neutralizing plasma, and memory B and T cells. These memory lymphocytes exhibit potent antiviral function, aiding in immune defense.

CELL (2021)

添加到收藏夹

Article Cell Biology

AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells

Shuai Wang et al.

Summary: This study found that AXL may serve as a novel receptor for SARS-CoV-2, playing an important role in promoting viral infection of the human respiratory system. AXL expression level is closely correlated with SARS-CoV-2 S level and could be a potential target for future clinical intervention strategies.

CELL RESEARCH (2021)

添加到收藏夹

Article Infectious Diseases

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020

Kathy Leung et al.

Summary: Two new lineages of SARS-CoV-2 with the N501Y mutation in the receptor-binding domain of the spike protein have spread rapidly in the United Kingdom. The 501Y lineage without amino acid deletion Delta 69/Delta 70 was estimated to be 10% more transmissible than the 501N lineage, while the 501Y lineage with amino acid deletion Delta 69/Delta 70 was estimated to be 75% more transmissible than the 501N lineage.

EUROSURVEILLANCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Immunology

Comparison of Four SARS-CoV-2 Neutralization Assays

Lydia Riepler et al.

Summary: Neutralizing antibodies are crucial for protection against viruses like SARS-CoV-2. This study compared four different assays for detecting these antibodies and found that they were all robust and yielded comparable results, indicating their reliability.

VACCINES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

Qianqian Li et al.

Summary: The 501Y.V2 variants of SARS-CoV-2 with multiple mutations are rapidly spreading from South Africa to other countries, showing reduced susceptibility to neutralizing antibodies and potential compromise of monoclonal antibodies and vaccines. Enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of transmission to mice.

CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Piyada Supasa et al.

Summary: Research on the UK-dominant variant B.1.1.7 shows that it is harder to neutralize than the parental virus, but widespread escape from antibodies or monoclonal antibodies has not been observed yet.

CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.

CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.

CELL (2021)

添加到收藏夹

Article Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen et al.

Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Microbiology

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Zhuoming Liu et al.

Summary: The study found that antibodies targeting the SARS-CoV-2 spike protein have escape mutations, different monoclonal antibodies have unique resistance profiles, some mutants are resistant to multiple antibodies while some variants can escape neutralization by convalescent sera. Comparing antibody-mediated mutations with circulating SARS-CoV-2 sequences revealed substitutions that may weaken neutralizing immune responses in some individuals, warranting further investigation.

CELL HOST & MICROBE (2021)

添加到收藏夹

Review Microbiology

The variant gambit: COVID-19's next move

Jessica A. Plante et al.

Summary: Despite the development of vaccines, COVID-19 caused by SARS-CoV-2 continues to be a global concern due to the emergence of new variants, raising worries about increased spread and potential impacts on immunity.

CELL HOST & MICROBE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Prevalence of SARS-CoV-2 in Karnataka, India

Manoj Mohanan et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier et al.

Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Detection of a SARS-CoV-2 variant of concern in South Africa

Houriiyah Tegally et al.

Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Rita E. Chen et al.

Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xuping Xie et al.

Summary: The study found that human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing key spike mutations from the newly emerged UK and SA variants.

NATURE MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Alexander Muik et al.

Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.

SCIENCE (2021)

添加到收藏夹

Letter Public, Environmental & Occupational Health

Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India

Anup Malani et al.

LANCET GLOBAL HEALTH (2021)

添加到收藏夹

Article Medicine, General & Internal

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Markus Hoffmann et al.

Summary: The study demonstrates that Camostat mesylate and its metabolite GBPA can block the spread of SARS-CoV-2 in human lung tissue, and the related protease inhibitor Nafamostat mesylate exhibits enhanced antiviral activity.

EBIOMEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Markus Hoffmann et al.

Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.

CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antibody evasion by the P.1 strain of SARS-CoV-2

Wanwisa Dejnirattisai et al.

Summary: Ending the SARS-CoV-2 pandemic requires global vaccination. New virus strains with mutations impact antibody responses, but some variants are less resistant than others. A monoclonal antibody can neutralize different variants and partially restore neutralization potency for other public antibodies.

CELL (2021)

添加到收藏夹

Article Microbiology

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera

Alona Kuzmina et al.

Summary: Vaccines that induce high levels of neutralizing antibodies are crucial in combating COVID-19, but some variants of SARS-CoV-2 show resistance to neutralization, raising concerns about vaccine efficacy.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Microbiology

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Venkata Viswanadh Edara et al.

Summary: Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations

Binquan Luan et al.

Summary: Recently emerged SARS-CoV-2 variants with mutations, such as N501Y, may enhance binding to hACE2. Molecular dynamics simulations show that Y501 in the mutated RBD can interact with Y41 and K353 in hACE2, potentially increasing the overall binding affinity by approximately 0.81 kcal center dot mol(-1). This binding dynamics may aid in designing more effective antibodies.

FEBS LETTERS (2021)

添加到收藏夹

Article Infectious Diseases

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

Dan Frampton et al.

Summary: This study describes the emergence of the B.1.1.7 variant of concern, its virological characteristics, and clinical severity in patients. Increased viral load was found in B.1.1.7 infection, but no association with severe disease was identified in the hospitalized cohort.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

Nuno R. Faria et al.

Summary: A new variant of concern, P.1, with 17 mutations including three spike protein mutations associated with increased binding to human ACE2 receptors, emerged in Manaus, Brazil between November 2020 and January 2021. Molecular analysis suggests P.1 may be 1.7- to 2.4-fold more transmissible and that previous infection may provide 54 to 79% protection against P.1 infection compared to other lineages. Enhanced global genomic surveillance of such variants is crucial for pandemic response.

SCIENCE (2021)

添加到收藏夹

Article Cell Biology

SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization

Markus Hoffmann et al.

Summary: Transmission of SARS-CoV-2 from humans to farmed mink and back raises concerns of genetic variants with potential increased threat to human health. Mutations in the spike protein of SARS-CoV-2 from mink allow efficient entry into human cells and inhibition by ACE2, while mutation Y453F reduces neutralization by certain antibodies authorized for COVID-19 therapy. Antibody responses induced by infection or specific treatments might not offer adequate protection against SARS-CoV-2 variants from mink.

CELL REPORTS (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

Mark S. Graham et al.

Summary: The study showed that the B.1.1.7 variant did not result in changes in COVID-19 symptoms or duration of illness, and there was no significant increase in reinfection rate compared to previous variants.

LANCET PUBLIC HEALTH (2021)

添加到收藏夹

Article Cell Biology

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Tyler N. Starr et al.

Summary: The study mapped mutations to the SARS-CoV-2 spike receptor-binding domain that escape binding by certain monoclonal antibodies. These mutations are concentrated in specific lineages of SARS-CoV-2. The authors suggest diversifying the epitopes targeted by antibodies and antibody cocktails to make them more resilient to SARS-CoV-2 antigenic evolution.

CELL REPORTS MEDICINE (2021)

添加到收藏夹

Letter Immunology

Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August-October 2020

Sitanshu Sekhar Kar et al.

Summary: The seropositivity for severe acute respiratory syndrome coronavirus 2 infection in Puducherry, India increased significantly over a period of 2 months, showing a higher prevalence compared to the number of diagnosed cases.

EMERGING INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Vanessa Monteil et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Qianqian Li et al.

CELL (2020)

添加到收藏夹

Article Immunology

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Fabian Schmidt et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

Thomas Mandel Clausen et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Johanna Hansen et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Distinct conformational states of SARS-CoV-2 spike protein

Yongfei Cai et al.

SCIENCE (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial

Bruno M. Tomazini et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Immunology

Broad and strong memory CD4+and CD8+T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Yanchun Peng et al.

NATURE IMMUNOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Neuropilin-1 is a host factor for SARS-CoV-2 infection

James L. Daly et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Ludovico Cantuti-Castelvetri et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

添加到收藏夹

Article Virology

Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization

Hannah Kleine-Weber et al.

JOURNAL OF VIROLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells

Constantin Brinkmann et al.

PLOS ONE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Differential Sensitivity of Bat Cells to Infection by Enveloped RNA Viruses: Coronaviruses, Paramyxoviruses, Filoviruses, and Influenza Viruses

Markus Hoffmann et al.

PLOS ONE (2013)

添加到收藏夹

Article Multidisciplinary Sciences

A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon

Marianne Berger Rentsch et al.

PLOS ONE (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

K Kuba et al.

NATURE MEDICINE (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.